Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) regularly issues news and updates about its application of artificial intelligence and machine learning to drug discovery and development. Company announcements highlight how its proprietary platforms bfLEAP® and bfPREP™ are used to analyze complex biomedical and clinical datasets and to support precision medicine strategies.
Investors and industry observers following BFRG news can expect coverage of collaborations with biopharmaceutical partners, such as work with Eleison Pharmaceuticals on oncology clinical trial data, and commercial relationships with organizations like Sygnature Discovery. Updates often describe how BullFrog AI’s technology is deployed to prepare and standardize legacy clinical records, identify biologically meaningful patient subgroups, and inform trial optimization and patient stratification efforts.
News items also discuss scientific validation milestones, including acceptance of abstracts for presentation at major oncology conferences such as the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. These communications provide detail on how BullFrog AI’s causal AI and human-in-the-loop workflows are applied to real-world datasets in areas like pancreatic cancer and other difficult-to-treat conditions.
In addition, BullFrog AI issues shareholder letters, webinar invitations, and whitepaper announcements that describe its enterprise-grade platform architecture, data preparation capabilities, and AI agent workflows. Readers of this news feed can use it to track the company’s commercial progress, scientific collaborations, technology enhancements, and capital markets developments as disclosed through press releases and related communications.
BullFrog AI (NASDAQ: BFRG) regained compliance with Nasdaq Listing Rule 5550(b)(1) by restoring minimum stockholders’ equity of $2,500,000 as of April 21, 2026. Compliance was achieved through sales under its at-the-market facility and an equity line of credit, extending cash runway into late 2027.
The company will be subject to a mandatory Nasdaq panel monitor for one year beginning April 21, 2026; a repeat noncompliance during that period could lead to prompt delisting procedures but allows a hearing request.
BullFrog AI (NASDAQ: BFRG) will exhibit at the American Association for Cancer Research Annual Meeting 2026 in San Diego from April 17-22, showcasing its end-to-end AI-driven drug discovery and development workflow at booth 2957.
Company representatives will be available for meetings and inquiries; contact Steven Seegers for scheduling.
BullFrog AI (Nasdaq: BFRG) announced a commercial feasibility agreement with a top 5 global pharmaceutical company on March 30, 2026 to identify drug targets for major depressive disorder using its bfLEAP® platform. The company raised financing that it says secures runway into late 2027 and launched bfARENAS™ to complete its end-to-end AI stack.
BullFrog AI (NASDAQ: BFRG) announced a commercial agreement dated March 30, 2026 with a top-5 global pharmaceutical company to apply its bfLEAP® platform to identify and prioritize novel therapeutic targets in major depressive disorder (MDD). The deal includes exclusive access to a target candidate and positions BullFrog AI as a partner in the Customer’s discovery and clinical development program for MDD.
The release cites the MDD market at >$8 billion in 2025 and rising toward >$11 billion by 2032, and notes the company will file a Form 8-K with additional agreement details.
BullFrog AI (NASDAQ: BFRG) unveiled bfARENAS™, a scenario-based decision engine to strengthen its end-to-end AI intelligence workflow for drug target discovery and clinical trial strategy.
The tool frames strategic scenarios as inputs to generate transparent, risk-balanced R&D portfolio recommendations. A webinar on bfARENAS™ is scheduled for March 27, 2026 at 11 a.m. ET.
BullFrog AI (NASDAQ: BFRG) will host a webinar on March 27, 2026 at 11 a.m. ET to introduce a new precision AI scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. The capability complements bfPREP and bfLEAP by adding a strategic decision‑support layer.
The platform compares drug programs and trial designs without arbitrary scores, tests decisions against multiple scenarios, and produces auditable, assumption‑driven outputs to support governance, cross‑functional alignment, and trial optimization.
BullFrog AI (NASDAQ: BFRG) will launch a new scenario-based decision engine on March 25, 2026 to augment its bfPREP and bfLEAP platforms. The capability evaluates drug programs, trial designs, and strategic portfolio options across explicit scenarios to surface robust, risk-balanced R&D portfolios.
Key features include multi-scenario testing (e.g., capital-constrained, US-first, global), preservation of portfolio diversity, and identification of programs that succeed across multiple strategic futures.
BullFrog AI (NASDAQ: BFRG) published a white paper, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” dated January 27, 2026. The paper explains how BullFrog’s bfPREP platform converts noisy, document-heavy biomedical data into standardized, AI-ready datasets by recognizing reliable patterns and producing clinically contextualized formats. It presents a three-pillar harmonization framework: (1) engineering clinically meaningful derived features, (2) producing reliable categorical variables and harmonized schemas, and (3) converting unstructured clinical documents into analysis-ready tables. The company positions bfPREP as the first step in its analytical toolkit to reduce time spent data-wrangling and support decision-making in drug development.
BullFrog AI (NASDAQ: BFRG) reported that its bfLEAP® platform identified treatment-effect heterogeneity and key biomarkers in a post-hoc analysis of the randomized phase 3 trial TH-CR-302, finding an almost threefold increase in mean survival from control to treatment arms in specific pancreatic cancer subgroups.
Findings will be presented at the ASCO GI Symposium on Jan. 9, 2026 (poster B) and will appear in the Journal of Clinical Oncology supplement. The analysis, conducted with Eleison Pharmaceuticals and Moffitt Cancer Center authors, highlights bfLEAP® and bfPREP™ as tools for data-driven patient clustering, early predictor identification, and precision-oncology stratification in glufosfamide development.
BullFrog AI (NASDAQ: BFRG) published its 2025 annual letter highlighting commercialization progress, technology milestones and 2026 catalysts. Key developments include a signed commercial collaboration with Sygnature Discovery expected to generate significant revenue through 2028, a real-world deployment with Eleison Pharmaceuticals in a pivotal Phase 3 oncology program, and the launch of bfPREP, an AI data‑preparation module that the company says can reduce data prep timelines from months to days. The company reports an annual burn of approximately $6.2 million and has financing flexibility via a $10 million equity line and an ATM. Near-term catalysts include the public presentation of Eleison results at ASCO on January 9, 2026 and ongoing advanced discussions with large pharmaceutical partners.